Printer Friendly

New Spacer From Artimplant Receives CE-mark.

STOCKHOLM, Sweden -- The biomaterials company Artimplant (STO:ARTIB), has received CE mark for its Artelon(R) DRU Spacer.

The spacer is intended for treatment of osteoarthritis in the distal radioulnar (DRU) joint of the wrist.

This is one of four products under the recent development and license agreements with Small Bone innovations, LLC (SBI).

Osteoarthritis in the distal radioulnar joint of the wrist

Fractures in the wrist region often results in complications. One of them could be osteoarthritis (OA) in the joint surface between distal radius and ulna. OA of the DRU joint often leads to ulnar wrist pain, limitation of forearm rotation and reduced grip strength, all of which limit activities of daily living. With Artelon(R) DRU Spacer the forearm will function in a natural way.

The field of application for Artelon(R) DRU Spacer is relatively limited and today the number of surgeries is estimated to about 3 000 annually on a global basis.

Artelon(R) - a unique biomaterial

Artelon(R) DRU Spacer is made of Artelon(R), a unique long-term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility in hard and soft tissue - Artelon(R) offers new solutions to unmet clinical needs in several therapy areas.

About Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.

About SBI

Small Bone Innovations, LLC (SBI) was founded in 2004 by Viscogliosi Bros., LLC, (VB), the New York-based merchant banking firm that specializes in the musculoskeletal /orthopedic sector. VB created SBI as the first company to focus purely on small bone & joint science. By integrating established companies and professionals in the field, SBI today offers a broad , clinically proven portfolio of products and technology to treat trauma and diseases in small bones & joints.

VB's acquisitions and technology licenses include: Avanta Orthopaedics, Inc. (finger/hand/wrist/elbow arthroplasty and trauma products - USA); Envision Manufacturing, Inc.(implant manufacturing - USA); Actipore (TM) (porous metal technology - Canada); Artelon (R)(biologically active & biodegradable technology - Sweden); Xtremi-T, LLC (bioabsorbable trauma technology - USA); and Fixano, S.A.S. (broad line of small bone & joint implants - France).

For more information, visit:

About Viscogliosi Bros., LLC

Established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G. Viscogliosi in New York City in 1999, VB was the first venture capital/private equity and merchant banking firm dedicated to the musculoskeletal/orthopedics sector of the health care industry. Today, VB is a leading independent firm with a mission to create, build and finance companies founded on innovations developed by surgeons and uniquely focused on "life changing" musculoskeletal/orthopedic technologies. VB has worldwide surgeon, industry and trade relationships and significant financial expertise in the musculoskeletal/orthopedic sector.

As principals of VB, the Viscogliosi brothers have a combined total of more than 35 years experience analyzing and investing in the musculoskeletal/orthopedics sector. They have pioneered innovative financial, strategic and management initiatives for companies in the sector, from start-up, seed and development stage all the way to exit, while helping thousands of people lead better lives through the orthopedic and spinal products marketed and sold by the companies they have assisted in financing and developing.

For more information visit:

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This information was brought to you by Waymaker
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 13, 2006
Previous Article:Oxford Automotive ApS to Combine with Wagon PLC.
Next Article:Washington Mutual Launches National Advertising Campaign in Support of Its New WaMu Free Checking(TM) Account, Stirs Up the Industry.

Related Articles
CE mark increases machine safety and prices.
A cure for BGA's warped sense of humor: rework can result in BGA warpage--find out how it can be prevented.
Typing of Borrelia relapsing fever group strains.
Transseptal suture to secure middle meatal spacers.
Keep spacer in place so ears won't break.
EU reviewing comments for possible CE mark revisions.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters